Personal Capital Advisors
STRO icon

Personal Capital Advisors’s Sutro Biopharma STRO Stock Holding History

Personal Capital Advisors’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$90.5K Hold
1,120
– – ﹤0.01% 482
2022
Q3 		$62K Hold
1,120
– – ﹤0.01% 448
2022
Q2 		$58K Buy
+1,120
New +$62.6K ﹤0.01% 439

Other funds holding STRO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Personal Capital Advisors's STRO Position: Q4 2022 in Review

Personal Capital Advisors held its Sutro Biopharma (STRO) position steady in Q4 2022 at 1,120 shares worth $90.5K. The position accounts for ﹤0.01% of the portfolio, ranked #482.

Personal Capital Advisors first reported a position in STRO in Q2 2022 and has held it in 3 quarters since. 117 funds tracked by Wall St. Rank hold STRO as of Q4 2022.

  • Personal Capital Advisors held 1,120 shares of Sutro Biopharma worth $90.5K as of Q4 2022.
  • Personal Capital Advisors left its Sutro Biopharma share count unchanged in Q4 2022.
  • Sutro Biopharma made up ﹤0.01% of Personal Capital Advisors's portfolio in Q4 2022, its #482 holding.
  • Personal Capital Advisors first reported a position in Sutro Biopharma in Q2 2022 and has held it in 3 quarters since.
  • 117 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2022.

Based on Personal Capital Advisors's 13F filing for Q4 2022, filed 15 Feb 2023.